Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-15
2008-09-02
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07419956
ABSTRACT:
The present invention intends to provide a novel peptide and use thereof. More particularly, the present invention provides a novel peptide and a DNA encoding the same, a drug comprising the peptide or DNA, a screening method/screening kit for a compound or its salt that promotes or inhibits the activity of the peptide, a compound or its salt obtained by the screening, a drug comprising the compound or its salt, etc.The peptide of the invention and the DNA encoding the same are usable, e.g., for the diagnosis, treatment, prevention, etc. of digestive diseases, etc. Moreover, the peptide of the invention is useful as a reagent for screening a compound or its salt that promotes or inhibits the activity of the protein of the invention.
REFERENCES:
patent: WO 98/46620 (1998-10-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/63088 (1999-12-01), None
patent: WO 00/34334 (2000-06-01), None
patent: WO 00/52022 (2000-09-01), None
patent: WO 00/53753 (2000-09-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 00/73454 (2000-12-01), None
patent: WO 00/75327 (2000-12-01), None
patent: WO 01/16309 (2001-03-01), None
patent: WO 01/36465 (2001-05-01), None
Wells, 1990, Biochemistry 29:8509-8517.
Wechselberger, C. et al “The mammalian homologues of frog Bv8 are mainly expressed in spermatocytes,”FEBS Letters, (1999), 462, pp. 177-181.
Parker, R. et al, “Y-receptor-like genes GPR72 and GPR73: molecular cloning, genomic organisation and assignment to human chromosome 11q21.1 and 2p14 and mouse chromosome 9 and 6,”Biochemica et Biophysica Acta(2000), 1491, pp. 369-375.
Schweitz, H. et al, “MIT1, a black mamba toxin with a new and highly potent activity on intestinal contraction,”FEBS Letters(1999), 461, pp. 183-188.
Tatemoto, K. et al, “Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor,”Biochemical and Biophysical Communications(1998), 251, pp. 471-476.
Osinski, m. et al, “Cloning, expression and functional role of a nociceptin/orphanin FQ receptor in the porcine gastrointestinal tract,”European Journal of Pharmacology(1999), 365, pp. 281-289.
Fujii, R. et al, “Identification of Neuromedin U as the Cognate Ligand of the Orphan G Protein-coupled Receptor FM-3,”Journal of Biological Chemistry, (2000), 275 (28), pp. 21068-21074.
Bowie, J., et al, “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” (1990),Science, 247, pp. 1306-1310.
Wells, J., “Additivity of Mutational Effects in Proteins,”Biochemistry, (1990), vol. 29, pp. 8509-8517.
Hinuma Syuji
Masuda Yasushi
Ohtaki Tetsuya
Shintani Yasushi
Takatsu Yoshihiro
Chandra Gyan
Foley & Lardner LLP
Landsman Robert
Takeda Pharmaceutical Company Limited
LandOfFree
Isolated physiologically active peptide and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated physiologically active peptide and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated physiologically active peptide and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3969965